Genetic protection bill "could harm Swiss industry":w :
This article was originally published in Clinica
Biomedical research in Switzerland could grind to a halt if a proposed genetic protection bill is passed, a leading Swiss industrialist has warned. Basic immunology research into illnesses such as cancer, diabetes, multiple sclerosis, HIV and Alzheimer's disease would be unable to continue, claimed Fritz Gerber, chairman of Roche. The bill, he said, would "totally cripple" biomedical research in the country. The proposed bill, the subject of a referendum on June 7, would prohibit the production and sale of genetically modified animals or plants and prevent patents from being granted for any process linked to research involving them.
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.